Safety and Efficacy of Recombinant Grass Pollen Allergen Cocktail in the Treatment of Allergic Rhinoconjunctivitis

Allergopharma GmbH & Co. KG

Overview

The trial is performed to assess efficacy and safety of a recombinant grass Pollen allergen cocktail in allergic rhinoconjunctivitis

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Conditions

Allergy

Interventions

Recombinant grass pollenBIOLOGICAL

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Positive Skin Prick Test reaction to grass pollen * Positive RAST result to grass pollen * Positive Provocation Test result to grass pollen Exclusion Criteria: * Serious chronic diseases * Other relevant perennial allergies

Locations (1)

Allergopharma GmbH & Co. KG

Reinbek, Germany

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.